explore -WSS

explore

author：fashion 2025-09-29 21:25:47 - browse：644

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Air quality improving but still lags in Black, Hispanic communities

entertainment

WSS

Former medical device CEO who sold dummy, plastic parts convicted of fraud

First medicine developed to treat MASH expected to be approved soon

FDA reorg will put new emphasis on investigations, sources say

Healthy food access boosts outcomes in two studies

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Sen. Paul opposes bill to ban Chinese biotechs

leisure time

explore

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Cancer diagnosis changes perspective doctor, former hospital CEO

Malaria cases in Florida and Texas: Here’s what you need to know

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Alkermes shareholders re

Today's health inequities arise from racist U.S. history, say experts

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

After decades in use, heart stents finally beat placebo

explore

UnitedHealth sued over use of algorithm in Medicare Advantage plans

RSV shot was 90% effective at preventing hospitalizations in kids

FDA reorg will put new emphasis on investigations, sources say

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

FDA reorg will put new emphasis on investigations, sources say

How state and local governments are sidelining science

hotspot

entertainment

leisure time

leisure time